The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cited by
Sorted by citations
Items 301–400 of 1,029
Ganda, S., & Stenzel, M. H. (2019) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2019.101195 · Cited by 211
Goel, S., Ferreira, C. A., Chen, F., Ellison, P. A., Siamof, C. M., Barnhart, T. E., & Cai, W. (2017) · Advanced Materials · doi:10.1002/adma.201704367 · Cited by 208
MicroRNA Therapeutics in Cancer: Current Advances and Challenges
Sayed, S. R. E., Cristante, J., Guyon, L., Denis, J., Chabre, O., & Cherradi, N. (2021) · Cancers · doi:10.3390/cancers13112680 · Cited by 217
Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
Huo, D., Jiang, X., & Hu, Y. (2019) · Advanced Materials · doi:10.1002/adma.201904337 · Cited by 207
Qiao, Q., Liu, X., Yang, T., Cui, K., Kong, L., Yang, C., & Zhang, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.023 · Cited by 213
“Free drugs may fail to reach the desired site of effect with required dose, and the drugs in non-target organs may be associated with undesired side reactions 76 .”
Dendrimer‐based nanocarriers: a versatile platform for drug delivery
Hsu, H., Bugno, J., Lee, S., & Hong, S. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1409 · Cited by 206
Wang, Y., Wei, G., Zhang, X., Xu, F., Xiong, X., & Zhou, S. (2017) · Advanced Materials · doi:10.1002/adma.201605357 · Cited by 203
Malvajerd, S. S., Azadi, A., Izadi, Z., Kurd, M., Dara, T., Dibaei, M., Zadeh, M. S., Javar, H. A., & Hamidi, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00510 · Cited by 211
Recent developments in Pickering emulsions for biomedical applications
Harman, C. L. G., Patel, M., Guldin, S., & Davies, G. (2019) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2019.01.017 · Cited by 203
Elzoghby, A. O., Abdelmoneem, M. A., Hassanin, I. A., Elwakil, M. M. A., Elnaggar, M. A., Mokhtar, S., Fang, J., & Elkhodairy, K. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120355 · Cited by 203
“liver, spleen and lung compared to anionic and neutral particles [224].”
Toxicity of manufactured nanomaterials
Liu, Y., Zhu, S., Gu, Z., Chen, C., & Zhao, Y. (2021) · Particuology · doi:10.1016/j.partic.2021.11.007 · Cited by 214
Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy
Li, W., Liu, Z., Fontana, F., Ding, Y., Liu, D., Hirvonen, J. J., & Santos, H. A. (2018) · Advanced Materials · doi:10.1002/adma.201703740 · Cited by 206
Charge reversal nano-systems for tumor therapy
Zhang, P., Chen, D., Li, L., & Sun, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01221-8 · Cited by 210
“For the past decades, nano drug delivery systems (NDDSs) are one of the most promising strategies for controlled and targeted drug delivery [7].”
BackgroundLazzari, G., Couvreur, P., & Mura, S. (2017) · Polymer Chemistry · doi:10.1039/c7py00559h · Cited by 209
Prospects, challenges and current status of RNAi through insect feeding
Kunte, N., McGraw, E., Bell, S., Held, D. W., & Avila, L. A. (2019) · Pest Management Science · doi:10.1002/ps.5588 · Cited by 199
Computational and experimental approaches for investigating nanoparticle-based drug delivery systems
Ramezanpour, M., Leung, S. S. W., Delgado‐Magnero, K. H., Bashe, B. Y. M., Thewalt, J. L., & Tieleman, D. P. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.02.028 · Cited by 199
Metallic nanoparticles as drug delivery system for the treatment of cancer
Desai, N., Momin, M. M., Khan, T. A., Gharat, S., Ningthoujam, R. S., & Omri, A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1912008 · Cited by 204
Du, X. C., Kleitz, F., Li, X., Huang, H., Zhang, X., & Qiao, S. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707325 · Cited by 197
Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases
Salehi, B., Călina, D. C., Docea, A. O., Koirala, N., Aryal, S., Lombardo, D., Pasqua, L., Taheri, Y., Castillo, C. M. S., Martorell, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020430 · Cited by 199
In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery
Deepagan, V. G., Kwon, S., You, D. G., Nguyen, V. Q., Um, W., Ko, H., Lee, H., Jo, D., Kang, Y. M., & Park, J. H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.044 · Cited by 196
“In general, nanoparticles with spherical morphology an d diameter less than 100 nm have been shown to have minimal uptake by the reticuloendothe lial system [31].”
BackgroundRuan, S., Zhou, Y., Jiang, X., & Gao, H. (2021) · Advanced Science · doi:10.1002/advs.202004025 · Cited by 200
Zou, Y., Liu, Y., Yang, Z., Zhang, D., Lu, Y., Zheng, M., Xue, X., Geng, J., Chung, R., & Shi, B. (2018) · Advanced Materials · doi:10.1002/adma.201803717 · Cited by 203
Inhalation of peptide-loaded nanoparticles improves heart failure
Miragoli, M., Ceriotti, P., Iafisco, M., Vacchiano, M., Salvarani, N., Alogna, A., Carullo, P., Ramirez-Rodríguez, G. B., Patrício, T., Esposti, L. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6205 · Cited by 194
Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
Xu, C., Lu, Z.-D., Luo, Y., Liu, Y., Cao, Z., Shen, S., Li, H., Liu, J., Chen, K., Chen, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06522-5 · Cited by 199
Mahato, K., Nagpal, S., Shah, M. A., Srivastava, A., Maurya, P. K., Roy, S., Jaiswal, A. K., Singh, R., & Chandra, P. (2019) · 3 Biotech · doi:10.1007/s13205-019-1577-z · Cited by 202
Capping gold nanoparticles with albumin to improve their biomedical properties
Bolaños, K., Kogan, M. J., & Araya, E. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s210992 · Cited by 194
“Interesting functional drug delivery systems can be obtained fromAuNPs, which possess numerous useful properties such as a high surface area, protection of cargo molecules from degradation, and energy absorption and emission dependent on their size, shape and surface modification, which will be subsequently described.…”
BackgroundSmart materials for drug delivery and cancer therapy
Yang, Y., Zeng, W., Huang, P., Zeng, X., & Mei, L. (2020) · Open Research (University of Surrey) · doi:10.1002/viw.20200042 · Cited by 194
Magnetic nanoparticles for cancer theranostics: Advances and prospects
Li, X., Li, W., Wang, M., & Liao, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.042 · Cited by 201
Biomedical Metal–Organic Framework Materials: Perspectives and Challenges
Wang, A., Walden, M., Ettlinger, R. L., Kiessling, F. M., Gassensmith, J. J., Lammers, T., Wuttke, S., & Peña, Q. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202308589 · Cited by 213
Kim, A., Ng, W. B., Bernt, W., & Cho, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-38915-x · Cited by 193
Electrospun Nanofibers for Drug Delivery and Biosensing
Cleeton, C., Keirouz, A., Chen, X., & Radacsi, N. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00853 · Cited by 197
Green nanotechnology-based zinc oxide (ZnO) nanomaterials for biomedical applications: a review
Medina-Cruz, D., Mostafavi, E., Vernet-Crua, A., Barabadi, H., Shah, V., Cholula-Diaz, J. L., Guisbiers, G., & Webster, T. J. (2020) · Journal of Physics Materials · doi:10.1088/2515-7639/ab8186 · Cited by 200
“Consequently, the use of nanotechnology has become more popular, as it can be applied towards cancer treatment and overcome substantial drawbacks (of the traditional treatment options) without experiencing toxicity to healthy tissues (Blanco et al 2015, Mostafavi et al 2019).”
Cooperativity Principles in Self-Assembled Nanomedicine
Li, Y., Wang, Y., Huang, G., & Gao, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00195 · Cited by 191
Havelikar, U. A., Ghorpade, K. B., Kumar, A., Patel, A., Singh, M., Banjare, N., & Gupta, P. N. (2024) · Discover Nano · doi:10.1186/s11671-024-04118-1 · Cited by 220
“NPs can improve the stability and solubility of enclosed substances, aid in the transport across membranes, and extend the duration of circulation, thus enhancing both safety and effectiveness [5, 6].”
BackgroundCovalent Organic Frameworks: From Materials Design to Biomedical Application
Zhao, F., Liu, H., Mathe, S., Dong, A., & Zhang, J. (2017) · Nanomaterials · doi:10.3390/nano8010015 · Cited by 191
da Rocha, M. C. O., da Silva, P. B., Radicchi, M. A., Andrade, B. Y. G., de Oliveira, J. V., Venus, T., Merker, C., Estrela‐Lopis, I., Longo, J. P. F., & Báo, S. N. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00604-7 · Cited by 191
“In addition, negative charged particles tend to have an increased plasma circulation time [25, 26].”
BackgroundTumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203
Dang, X., Gu, L., Qi, J., Correa, S., Zhang, G., Belcher, A. M., & Hammond, P. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521175113 · Cited by 190
“The completed LbL NPs, with a layered structure consisting of NIR-II emissive core/PLA/DXS/PLA/HA, possessed zeta potentials of approximately −30 mV and hydrodynamic diameters within the optimal range (10–200 nm) for systemic delivery (22, 23), except the SWNT (280 nm) because its unique elongated shape was not recogn…”
BackgroundStéen, E. J. L., Edem, P. E., Nørregaard, K., Jørgensen, J. T., Shalgunov, V., Kjær, A., & Herth, M. M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.021 · Cited by 194
“In particular the size, surface properties, shape and charge can alter accumulation [5,16].”
BackgroundBrumano, L. P., da Silva, F. V. S., Costa-Silva, T. A., Apolinário, A. C., Santos, J. H. P. M., Kleingesinds, E. K., Monteiro, G., Rangel‐Yagui, C. D. O., Benyahia, B., & Pessoa, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00212 · Cited by 189
Engineering the drug carrier biointerface to overcome biological barriers to drug delivery
Finbloom, J. A., Sousa, F., Stevens, M. M., & Desai, T. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.007 · Cited by 195
DNA-Based Nanostructures for Live-Cell Analysis
Ebrahimi, S. B., Samanta, D., & Mirkin, C. A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04978 · Cited by 190
Spatiotemporal control of CRISPR/Cas9 gene editing
Zhuo, C., Zhang, J., Lee, J., Jiao, J., Cheng, D., Liu, L., Kim, H., Tao, Y., & Li, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00645-w · Cited by 196
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Hazaveh, M. N., Khosravi, S., Andani, M. K., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 202
Non-spherical micro- and nanoparticles in nanomedicine
Zhu, X., Vo, C. L.-N., Taylor, M., & Smith, B. R. (2019) · Materials Horizons · doi:10.1039/c8mh01527a · Cited by 191
Guo, X., Liu, F., Deng, J., Dai, P., Qin, Y., Li, Z., Wang, B., Fan, A., Wang, Z., & Zhao, Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c00764 · Cited by 190
Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth
Zelepukin, I. V., Yaremenko, A. V., Shipunova, V. O., Babenyshev, A., Balalaeva, I. V., Nikitin, P. I., Deyev, S. M., & Nikitin, M. P. (2018) · Nanoscale · doi:10.1039/c8nr07730d · Cited by 189
Micro/Nanorobot: A Promising Targeted Drug Delivery System
Hu, M., Ge, X., Chen, X., Mao, W., Qian, X., & Yuan, W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070665 · Cited by 191
“What is more, only less than one percent of nanoparticles could accumulate in tumors [8].”
BackgroundWan, M. M., Chen, H., Wang, Z. D., Liu, Z. Y., Yu, Y. Q., Li, L., Miao, Z., Wang, X. W., Wang, Q., Mao, C., et al. (2020) · Advanced Science · doi:10.1002/advs.202002525 · Cited by 187
Miyazawa, T., Itaya, M., Burdeos, G. C., Nakagawa, K., & Miyazawa, T. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s298606 · Cited by 198
“The opsonized nanoparticles interact with receptors on the surface of macrophages and are transported to phagosomes and fused with lysosomes for degradation or elimination from the body.(111) It has been reported that PLGA nanoparticles, which are not coated with any surfactant, are opsonized by non-specific adsorptio…”
BackgroundApplications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Zhou, F., Zheng, L., Huang, X., & Liu, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 188
Recent advancements in biocompatible inorganic nanoparticles towards biomedical applications
Jiao, M., Zhang, P., Meng, J., Li, Y., Liu, C., Luo, X., & Gao, M. (2017) · Biomaterials Science · doi:10.1039/c7bm01020f · Cited by 191
Walking the line: The fate of nanomaterials at biological barriers
Meng, H., Leong, W., Leong, K. W., Chen, C., & Zhao, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.056 · Cited by 187
“Potential safety concerns regarding nanotherapeutics are growing as work to develop solutions to the problem of their nonspecific distribution is still ongoing [54, 55].”
BackgroundExploiting metabolic glycoengineering to advance healthcare
Agatemor, C., Buettner, M. J., Ariss, R., Muthiah, K., Saeui, C. T., & Yarema, K. J. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0126-y · Cited by 189
Sharma, H., & Mondal, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176280 · Cited by 185
“Further, NPs sized >200 nm undergo higher accumulation in organs such as the liver and spleen [57].”
BackgroundRicketts, T. D., Prieto‐Domínguez, N., Gowda, P. S., & Ubil, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642285 · Cited by 186
Bisphosphonate conjugation for bone specific drug targeting
Farrell, K. B., Karpeisky, A. M., Thamm, D. H., & Zinnen, S. P. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.06.007 · Cited by 186
“The particle size and other properties of large conglomerates should also be considered, as extravasation may be limited for very large particles (Ishida et al., 1999; Blanco et al., 2015).”
BackgroundHe, L., Nie, T., Xia, X., Liu, T., Huang, Y., Wang, X., & Chen, T. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201901240 · Cited by 184
Self-Assembling Nucleic Acid Nanostructures Functionalized with Aptamers
Krissanaprasit, A., Key, C. M., Pontula, S., & LaBean, T. H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01332 · Cited by 187
Tsai, Y.-C., Vijayaraghavan, P., Chiang, W., Chen, H., Liu, T., Shen, M., Omoto, A., Kamimura, M., Soga, K., & Chiu, H. (2018) · Theranostics · doi:10.7150/thno.22482 · Cited by 183
“Besides exploiting the tumor-related enhanced permeation and retention (EPR) effects, selective delivery of nanomedicines to brain tumors has usually been achieved by targeting ligands, such as transferrin, cyclic arginine-glycine-aspartic acid (cRGD), and angiopep-2 [14-16].”
BackgroundEfficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.006 · Cited by 185
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182
Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
Hao, M., Hou, S., Li, W., Li, K., Xue, L., Hu, Q., Zhu, L., Chen, Y., Sun, H., Ju, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6667 · Cited by 183
“However, delivering the compounds into cells of interest, such as T cells, is challenging because the harsh microenvironment of solid tumors can restrict the entry of compounds into specific cells (51).”
BackgroundCheng, H. B., Fan, J., Zhao, L., Fan, G., Zheng, R., Qiu, X., Yu, X., Li, S., & Zhang, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.05.004 · Cited by 181
Progress on Modulating Tumor‐Associated Macrophages with Biomaterials
Sylvestre, M., Crane, C. A., & Pun, S. H. (2019) · Advanced Materials · doi:10.1002/adma.201902007 · Cited by 183
Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review
Indoria, S., Singh, V., & Hsieh, M.-F. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119314 · Cited by 168
Nanovaccines: A game changing approach in the fight against infectious diseases
Priyanka, Abusalah, M. A. H., Chopra, H., Sharma, A., Mustafa, S. A., Choudhary, O. P., Sharma, M. K., Dhawan, M. K., Khosla, R., Loshali, A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115597 · Cited by 194
Crossing biological barriers with nanogels to improve drug delivery performance
Cuggino, J. C., Osorio‐Blanco, E. R., Gugliotta, L. M., Igarzabal, C. I. Á., & Calderón, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.005 · Cited by 183
Ding, L., Zhu, X., Wang, Y., Shi, B., Ling, X., Chen, H., Nan, W., Barrett, A., Guo, Z., Tao, W., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03021 · Cited by 180
Tang, H., Zhang, Y., Yang, T., Wang, C., Zhu, Y., Qiu, L., Liu, J., Song, Y., Zhou, L., Zhang, J., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01455-7 · Cited by 179
Zhang, N., Yan, F., Liang, X., Wu, M., Shen, Y., Chen, M., Xu, Y., Zou, G., Jiang, P., Tang, C., et al. (2018) · Theranostics · doi:10.7150/thno.23734 · Cited by 180
“Hydrophobic curcumin molecules are present in the hydrophobic domain of the lipid bilayer of cerasomes [46-49].”
BackgroundAhmadi, M., Ayyoubzadeh, S. M., Ghorbani‐Bidkorbeh, F., Shahhosseini, S., Dadashzadeh, S., Asadian, E., Mosayebnia, M., & Siavashy, S. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06914 · Cited by 178
Aptamer functionalized nanomaterials for biomedical applications: Recent advances and new horizons
Mahmoudpour, M., Ding, S., Lyu, Z., Ebrahimi, G., Du, D., Dolatabadi, J. E. N., Torbati, M., & Lin, Y. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101177 · Cited by 177
Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions
Kashkooli, F. M., Jakhmola, A., Hornsby, T. K., Tavakkoli, J., & Kolios, M. C. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.009 · Cited by 184
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Gallego‐Ortega, D., & Deng, W. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 190
“135 It is important to note that an additional barrier exists for plasmid DNA cargo, which must be transported into the nucleus for transcription and subsequent translation into proteins in the cytosol.”
BackgroundA review on novel methodologies for drug nanoparticle preparation: Microfluidic approach
Shrimal, P., Jadeja, G. C., & Patel, S. R. (2019) · Process Safety and Environmental Protection · doi:10.1016/j.cherd.2019.11.031 · Cited by 183
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
Gu, Z., Silva, C. G. D., van der Maaden, K., OSSENDORP, F. A., & Cruz, L. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111054 · Cited by 181
Zhang, J., Hu, K., Di, L., Wang, P., Liu, Z., Zhang, J., Yue, P., Song, W., Zhang, J., Chen, T., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113964 · Cited by 189
Liu, S., Wang, X., Yu, X., Cheng, Q., Johnson, L. T., Chatterjee, S., Zhang, D., Lee, S. M., Sun, Y., Lin, T., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09822 · Cited by 175
Enhancing in situ cancer vaccines using delivery technologies
Gong, N., Alameh, M., El-Mayta, R. D., Xue, L., Weissman, D., & Mitchell, M. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00974-9 · Cited by 197
Lázaro, I. A., Haddad, S., Rodrigo-Muñoz, J. M., Marshall, R. J., Sastre, B., del Pozo, V., Fairen‐Jiménez, D., & Forgan, R. S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b11652 · Cited by 182
Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
Jena, L., McErlean, E. M., & McCarthy, H. O. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00679-2 · Cited by 182
Polyglycerol Grafting Shields Nanoparticles from Protein Corona Formation to Avoid Macrophage Uptake
Zou, Y., Ito, S., Yoshino, F., Suzuki, Y., Zhao, L., & Komatsu, N. (2020) · ACS Nano · doi:10.1021/acsnano.0c02289 · Cited by 173
Dai, L., Yao, M., Fu, Z., Li, X., Zheng, X., Meng, S., Zhang, Y., Cai, K., Yang, H., & Zhao, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-30436-y · Cited by 176
Ultrasmall noble metal nanoparticles: Breakthroughs and biomedical implications
Jiang, X., Du, B., Huang, Y., & Zheng, J. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.006 · Cited by 178
Haripriyaa, M., & Suthindhiran, K. (2023) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-023-00569-y · Cited by 196
“The thermal diffusion changes of air molecules interacting with the particles in the inspiratory and expiratory airflows are the main factors that control nanoparticle deposition in the airways [52, 53].”
BackgroundZhang, R., Ahmed, T., Li, L. Y., Li, J., Abbasi, A. Z., & Wu, X. Y. (2016) · Nanoscale · doi:10.1039/c6nr08486a · Cited by 180
Chen, G., Jaskula‐Sztul, R., Esquibel, C. R., Lou, I., Zheng, Q., Dammalapati, A., Harrison, A. D., Eliceiri, K. W., Tang, W., Chen, H., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201604671 · Cited by 174
Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy
Zhan, Q., Yi, K., Qi, H., Li, S., Li, X., Wang, Q., Wang, Y., Liu, C., Qiu, M., Yuan, X., et al. (2020) · Theranostics · doi:10.7150/thno.45028 · Cited by 168
Designer DNA nanostructures for therapeutics
Jiang, S., Ge, Z., Mou, S., Yan, H., & Fan, C. (2020) · Chem · doi:10.1016/j.chempr.2020.10.025 · Cited by 174
Jyothi, V. G. S. S., Bulusu, R., Rao, B. V. K., Mulinti, P., Banda, S., Bolla, P. K., & Kommineni, N. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122022 · Cited by 184
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
“In addition, biological barriers must be considered during the design and development of the chosen nanocarrier (Blanco et al., 2015).”
BackgroundNanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 177
Polymeric Nanoparticles with Neglectable Protein Corona
Alberg, I., Kramer, S., Schinnerer, M., Hu, Q., Seidl, C. I., Leps, C., Drude, N., Möckel, D., Rijcken, C. J. F., Lammers, T., et al. (2020) · Small · doi:10.1002/smll.201907574 · Cited by 178
Ma, B., Xu, H., Zhuang, W., Wang, Y., Li, G., & Wang, Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c01012 · Cited by 176
Sun, L., Fan, M., Huang, D., Li, B., Xu, R., Gao, F., & Chen, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120761 · Cited by 178
Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy
Xia, W., Tao, Z., Zhu, B., Zhang, W., Liu, C., Chen, S., & Song, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179118 · Cited by 177
“When the cell membrane surface was functionalized, amount of protein (IgG and albumin) adsorbed on the particle surface was reduced by over 10-fold [108].”
BackgroundNanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives
Petrović, S., Bita, B. I., & Barbinta-Patrascu, M. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115842 · Cited by 186
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
